《制药行业数据分析(EFPIA_2010版)》由会员分享，可在线阅读，更多相关《制药行业数据分析(EFPIA_2010版)（41页珍藏版）》请在金锄头文库上搜索。
1、The Pharmaceutical Industry in Figures 2010 Edition S SUMMARYSUMMARY 1 E urope has a great deal to gain in health and economic terms from a strong and competitive indigenous research- based pharmaceutical sector. The research- based pharmaceutical industry is one of the few remaining leading high te
2、chnology industries in Europe, amounting to 17% of EU business R USA: $ million; Japan: million x 100 (e): estimate Source: EFPIA member associations, PhRMA, JPMA PHARMACEUTICAL R Eurostat (EU-27 trade data 1995-2009) The research-based pharmaceutical industry accounts for approximately 3.5% of tota
3、l EU manufacturing value added and for 17% of total EU business R R trade surplus: 52,200 million in 2008 (up from 7,100 in 1990). INDUSTRY (EFPIA total) (1) 1990 1995 2000 2005 2008 2009 Production 63,010 88,912 123,282 172,099 196,283 195,000 (e) Exports (2) 23,180 44,188 90,935 181,575 230,770 24
4、0,000 (e) Imports (2) 16,113 31,018 68,841 145,823 178,576 185,000 (e) Trade balance 7,067 13,170 22,094 35,752 52,194 55,000 (e) R China: 2005 data; Greece, Japan, Turkey: 2007 data Belgium, Bulgaria, Cyprus, Estonia, France, Ireland, Italy, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal,
5、 U.K., USA: provisional data Austria, Denmark, Germany, Greece, Sweden, EU-27: estimate Source: Eurostat, 12 March 2010, Science, technology and innovation in Europe, 2009 edition 12 B BIOPHARMACEUTICALSBIOPHARMACEUTICALS T he major health challenges facing Europe require new technologies. The appli
6、cation of human genomics knowledge to clinical practice and drug de- velopment will allow us to predict a patients response to treatment and create new “personalised” medicines according to genetic variations. The introduction of these new medicines will not only affect the global burden of disease
7、but also the pattern of care and patient management, with an operational shift from acute treatment to prevention and cure. Approximately one-fifth of the new molecular entities launched on the world market each year are now derived from biotechnology. Europes biotechnology sector is growing fast, a
8、lthough still not as fast as its US counterpart. In this context, competitive research is the key. The development of a strong and viable biomedical industry in Europe goes hand in hand with the maintenance of a competitive and innovative research-based industry in Europe. BIOPHARMACEUTICALS (2008)
9、Value in million Global USA Europe Canada Asia-Pacific Revenues 60,952 44,960 11,228 1,388 3,376 R North America: 53 projects; Asia (including Japan): 2 projects, Others: 5 projects). Major international vaccine manufactu- rers altogether had 20 manufacturing sites and 22 R Malta: 2004 data Belgium,
10、 France, Greece, Ireland, Italy, Malta, Netherlands, Norway, Poland, Romania, Slovenia, Sweden, United Kingdom: estimate Source: EFPIA member associations (official figures) EFPIA 2008 Units Austria 10,534 Belgium 29,600 Bulgaria n.a. Croatia n.a. Cyprus 1,140 Czech Republic 2,200 Denmark 17,019 Est
11、onia n.a. Finland 6,002 France 103,384 Germany 105,843 Greece 13,500 Hungary n.a. Iceland n.a. Ireland 24,500 Italy 69,500 Latvia n.a. Lithuania n.a. Malta 445 Netherlands 16,000 Norway 4,630 Poland 23,905 Portugal 10,244 Romania 22,000 Slovakia 2,000 Slovenia 7,100 Spain 40,385 Sweden 15,725 Switze
12、rland 35,400 United Kingdom 72,000 Total 633,056 15 T he research-based pharmaceutical industry is one of Europes major high- technology industrial employers. Recent studies carried out in some countries showed that the research-based pharmaceutical industry generates three to four times more employ
13、ment indirectly - upstream and downstream - than it does directly, a signi- ficant proportion being high value added jobs (e.g. clinical science, universities, etc). The industry directly employs about 633,100 people, of which 113,400 work in R Norway, U.K.: 2007 data; Netherlands: 2005 data; Malta:
14、 2004 data Denmark, France, Ireland, Italy, Norway, Portugal, Spain, Sweden, Switzerland: estimate Germany, Ireland, Norway, Switzerland: veterinary products excluded Source: EFPIA member associations (official figures) 17 P PHARMACEUTICAL PHARMACEUTICAL PRODUCTIONPRODUCTION W ith an estimated share
15、 of 38.1% of the world pharmaceutical production, the USA remains the primary manufacturing centre for medicines in the world, just ahead of Europe and Japan. Together, these three regions account for the bulk (approximately 82%) of the world pharmaceutical production. In 2008, EFPIA countries pharm
16、aceutical production was worth an estimated total of 196,300 mil- lion. According to EUROSTAT data, the pharmaceutical industry is the high techno- logy sector with the highest value added per person employed, well above the aver- age value for high-tech and manufacturing industries. The pharmaceutical industry is also the sector with the highest ratio of R Estonia, Malta: pharmacy sales only; Greece: including parallel exports Belgium (2008 provisional), France, Germany, Ire
